Obame Fatou Nsoure, Zini Roland, Souktani Rachid, Berdeaux Alain, Morin Didier
INSERM U841, équipe 3, Facultéde Médecine de Paris XII, 8 rue du Général Sarrail, F-94010, Créteil, France.
J Pharmacol Exp Ther. 2007 Oct;323(1):336-45. doi: 10.1124/jpet.107.124255. Epub 2007 Jul 19.
Opening of the permeability transition pore (PTP) is a key event in ischemia-reperfusion injury and several ligands of the peripheral benzodiazepine receptor (PBR), a mitochondrial outer membrane protein possibly associated with PTP, have been demonstrated as potent cardioprotective agents. Here, we investigated the mechanisms by which the specific PBR ligand 4'-chlorodiazepam (CDZ) protected the myocardium against ischemia-reperfusion. In either global or regional models of myocardial ischemia-reperfusion in rats, CDZ reduced infarct size in a dose-dependent manner (e.g., 11 +/- 1% of the area at risk at 10 mg/kg versus 31 +/- 3% in control; p < 0.05) and to a similar extent as ischemic or diazoxide-induced preconditioning. CDZ (10 mg/kg) reduced apoptosis (terminal deoxynucleotidyl transferase dUTP nick-end labeling staining), restored mitochondrial recovery, improved oxidative phosphorylation parameters, and reduced mitochondrial membrane permeabilization with inhibition of cytochrome c and apoptosis-inducing factor releases. CDZ increased the resistance of mitochondria to Ca2+-induced PTP opening. All these cardioprotective effects of CDZ were associated with an improved stabilization of the association of Bcl-2 with the mitochondrial membrane and inhibition of the association of a cytosolic fragment of Bax, occurring during ischemia-reperfusion, with the outer mitochondrial membrane. In addition, the PTP opener atractyloside (20 microM) and the Bcl-2 inhibitor ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA14-1) (20 microM) abrogated CDZ-induced reduction of infarct size. These results demonstrate that PBR occupancy by CDZ renders the heart more resistant to ischemia-reperfusion injury by limiting mitochondrial membrane permeabilization. This is due to a reorganization of the balance between pro- and antiapoptotic proteins of the Bcl-2 family proteins at the level of mitochondrial membranes.
通透性转换孔(PTP)的开放是缺血再灌注损伤中的关键事件,外周苯二氮䓬受体(PBR)的几种配体已被证明是有效的心脏保护剂,PBR是一种可能与PTP相关的线粒体外膜蛋白。在此,我们研究了特异性PBR配体4'-氯地西泮(CDZ)保护心肌免受缺血再灌注损伤的机制。在大鼠心肌缺血再灌注的整体或局部模型中,CDZ以剂量依赖性方式减小梗死面积(例如,10mg/kg时梗死面积占危险区域的11±1%,而对照组为31±3%;p<0.05),且程度与缺血或二氮嗪诱导的预处理相似。CDZ(10mg/kg)减少凋亡(末端脱氧核苷酸转移酶dUTP缺口末端标记染色),恢复线粒体功能,改善氧化磷酸化参数,并减少线粒体膜通透性,抑制细胞色素c和凋亡诱导因子释放。CDZ增加线粒体对Ca2+诱导的PTP开放的抗性。CDZ的所有这些心脏保护作用都与缺血再灌注期间Bcl-2与线粒体膜结合的稳定性提高以及Bax胞质片段与线粒体外膜结合的抑制有关。此外,PTP开放剂苍术苷(20μM)和Bcl-2抑制剂乙基-2-氨基-6-溴-4-(1-氰基-2-乙氧基-2-氧代乙基)-4H-色烯-3-羧酸酯(HA14-1)(20μM)消除了CDZ诱导的梗死面积减小。这些结果表明,CDZ占据PBR可通过限制线粒体膜通透性使心脏对缺血再灌注损伤更具抗性。这是由于Bcl-2家族蛋白的促凋亡和抗凋亡蛋白在线粒体膜水平上的平衡发生了重新组织。